Landfar Bio-medicine Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Changqiao You

Chief executive officer

CN¥1.9m

Total compensation

CEO salary percentage	n/a
CEO tenure	2.4yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.4yrs

Recent management updates

Recent updates

Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Apr 17

Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Mar 01

CEO

Changqiao You (50 yo)

2.4yrs

Tenure

CN¥1,858,800

Compensation

Mr. Changqiao You is GM & Director of Landfar Bio-medicine Co., Ltd.

Board Members

Name	Position	Tenure	Compensation	Ownership
Changqiao You	GM & Director	2.4yrs	CN¥1.86m	no data
Weihua Cu	Independent Director	5.8yrs	CN¥96.00k	no data
Yuan Chen	Director	2.4yrs	no data	no data
Chen Shen	Supervisor	5.8yrs	no data	no data
Yun Yang	Chairman	2.4yrs	CN¥1.05m	no data
Haiyi Cao	Director	2.4yrs	no data	no data
Yaqing Zhao	Independent Director	2.4yrs	CN¥96.00k	no data
Ping Zhao	Independent Director	2.4yrs	CN¥96.00k	no data
Jian Qiu	Chairman of the Supervisory Board	2.4yrs	no data	no data
Feng Yan	Employee Representative Supervisor	2.2yrs	no data	no data

2.4yrs

Average Tenure

43.5yo

Average Age

Experienced Board: 000504's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Landfar Bio-medicine Management

Management criteria checks 0/4

Key information

Recent management updates

Landfar Bio-medicine Co., Ltd, Annual General Meeting, May 24, 2024

Less than half of directors are independent

NanHua Bio-medicine Co., Ltd, Annual General Meeting, May 25, 2022

Recent updates

First quarter 2024 earnings released: CN¥0.008 loss per share (vs CN¥0.006 loss in 1Q 2023)

Landfar Bio-medicine Co., Ltd, Annual General Meeting, May 24, 2024

Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Chongqing International Trust Co., Ltd. acquired 10.8% stake in Landfar Bio-medicine Co., Ltd (SZSE:000504) from Shanghai Heping Dazong Equity Investment Fund Management Co., Ltd for CNY 0.03 million.

Landfar Bio-medicine Co., Ltd to Report Q1, 2024 Results on Apr 30, 2024

Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Less than half of directors are independent

Landfar Bio-medicine Co., Ltd to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.033 (vs CN¥0.005 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.023 loss per share (vs CN¥0.007 profit in 2Q 2022)

New minor risk - Share price stability

Now 22% undervalued after recent price drop

Full year 2022 earnings released: CN¥0.04 loss per share (vs CN¥0.06 loss in FY 2021)

Third quarter 2022 earnings released: CN¥0.005 loss per share (vs CN¥0.007 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.007 (vs CN¥0.023 loss in 2Q 2021)

NanHua Bio-medicine Co., Ltd, Annual General Meeting, May 25, 2022

First quarter 2022 earnings released: EPS: CN¥0.001 (vs CN¥0.003 in 1Q 2021)

Third quarter 2021 earnings released: CN¥0.007 loss per share (vs CN¥0.004 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.023 loss per share (vs CN¥0.002 loss in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.005 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.03 (vs CN¥0.06 in FY 2019)

NanHua Bio-medicine Co., Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: CN¥13.58

New 90-day low: CN¥9.82

New 90-day low: CN¥12.15

New 90-day low: CN¥12.42

NanHua Bio-medicine Co., Ltd to Report Q3, 2020 Results on Oct 26, 2020

New 90-day high - CN¥14.24

NanHua Bio-medicine Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age